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1. Introduction 
The Human Immunodeficiency Virus type 1 (HIV-1) is a C-type enveloped retrovirus 
(classification based on morphology of retroviruses electron microscopy) of the Retroviridae 
family. It’s consisting in a genome of 2 positive stranded RNA molecules and a specific 
polymerase reverse transcriptase enzyme (RT). The viral RNA is reverse transcribed by RT 
into a double-stranded DNA molecule which is then integrated into the genome of infected 
cells (figure 1). The virus is wrapped by a bilayer membrane derived from the host cell. 
Homotrimers of the viral glycoprotein gp160 are inserted in the envelope (figure 1). Several 
cellular proteins are also incorporated into the viral membrane with relative abundance, 
including MHC class I and II molecules and intracellular adhesion molecule. Lentiviruses, to 
which HIV belongs, cause disease with a 'slow' evolution preceded by a period of clinical 
latency. Apart from humans, lentiviruses infect several other species of mammals such as  
 
 
 
 
Fig. 1. Schematic representation of the HIV-1 particle. Two copies of the viral positive 
stranded RNA genome are packed in the capsid. Viral enzymes: reverse transcriptase (RT), 
integrase (IN), protease (Pr) and structural proteins; capsid (CA), nucleocapsid (NC), matrix 
(MA) and p6 are inside the particle together with the viral regulatory protein Vpr and the 
cellular protein cyclophilin (Phogat et al., 2007). 
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primates (Simian Immunodeficiency Virus, SIV), feline and ovine. Infection by HIV-1 causes 
a very rapid destruction of the majority of T cells memory CD4+/CCR5+ and especially 
those residing in the intestinal mucosa. 
Although antiretroviral therapy for HIV infection prevents AIDS-related complications and 
prolongs life, it does not fully restore health. Long-term treated patients remain at higher 
than expected risk for a number of complications typically associated with aging, including 
cardiovascular disease, cancer, osteoporosis, and other end-organ diseases. The potential 
effect of HIV on health is perhaps most clearly exhibited by a number of immunologic 
abnormalities that persist despite effective suppression of HIV replication. These changes 
are consistent with some of the changes to the adaptive immune system that are seen in the 
very old ("immunosenescence") and that are likely related in part to persistent 
inflammation. HIV-associated inflammation and immunosenescence have been implicated 
as causally related to the premature onset of other end-organ diseases.  
This review summarizes the importance to generate immune responses against HIV-1 
glycoprotein in further vaccinal approaches and detail the complexity of the envelope 
structure and the relative high HIV-1 glycoprotein immunogenicity.  
2. Molecular basis of HIV envelope glycoprotein 
2.1 HIV-1 envelope glycoprotein 
The gp120 (SU) and gp41 (TM) envelope glycoproteins are encoded by the HIV gene env. 
This gene codes for an Env precursor polyprotein (p90) which undergoes post-
transcriptional modifications as glycosylations resulting in the gp160 precursor. It is 
interesting to note that the HIV cleavage sequence is highly conserved (Veronese et al., 1985) 
and is included in one of the most conserved domains within gp120 (C5). Gp160 is produced 
as an inactive precursor in the rough endoplasmic reticulum and subjected to extensive N-
glycosylation resulting in high mannose chains linked to Asn residues at either Asn-X-Ser or 
Asn-X-Thr glycosylation sites. The gp160 are sorted through the constitutive secretory 
pathway of the infected cells (Moulard and Decroly, 2000). Once transported to the cellular 
plasma membrane, trimeric gp120–gp41 complexes are incorporated into budding virus for 
the release of new infectious particles. Before its anchoring on the surface, gp160 is cleaved 
by a host protease named furine in two sub-units associated by non-covalent interactions 
(gp120 on the surface and the transmembrane gp 41) (Hallenberger et al., 1992). Envelope 
glycoproteins form trimeric spicules of gp120-gp41 complexes on the surface of the virus 
conferring viral tropism (Chan and Kim, 1998). Env is also involved in the interaction, 
recognition and the fusion of the viral and cellular membranes leading to the introduction of 
the viral genome into the cytoplasm of the target cells. The Env spikes are thought to be 
trimeric and structure-based models have been proposed (figures 2&3). Cryoelectronic 
microscopy tomography shows heterotrimeric complexes (Roux and Taylor, 2007; Briggs et 
al., 2009). However, despite intensive efforts, the arrangement and orientation of the loop-
deleted gp120 core atomic structures within a native Env spike and their association with 
the gp41 subunits have remained largely speculative. 
The entry of virus into the target cell involves the fusion of cell membranes and the viral 
envelope. Whereas, the recognition of the target cell by the gp120 is not sufficient to directly 
cause membrane fusion and mediate the injection of viral genome. The adsorption of HIV-1 
on cell surface is mediated by interactions between envelope glycoproteins and two types of 
surface molecules: attachment factors (or adhesion receptors) and coreceptors (figure2). 
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Coreceptors are actively involved in the penetration of the virus and are selective for the 
entry of the virion into the host cells depending on their tropism. 
 
 
Fig. 2. Schematic representation of the interaction between envelope glycoprotein and viral 
receptors. On the left, a surface rendered cryo-electron microscopy tomographic image of 
HIV-1. Viral spikes are blue and the viral surface is grey. On the right is shown a structure-
based model of the envelope glycoproteins of HIV. Trimeric HIV‑1 gp120 proteins shown in 
cyan bind to the primary receptor, CD4. Following conformational changes, the gp120–CD4 
complex binds the chemotaxis receptor adapted from (Karlsson Hedestam et al., 2008). 
2.2 Gp120 envelope glycoprotein 
Gp 120 glycoprotein represents the external part of the envelope glycoprotein of HIV with a 
molecular weight of 120 kDa. It contains 480aa with 9 disulfide bridges and 20 to 24 N-
glycosylation sites. Gp120 is involved in the earlier steps of the infection of target cells. 
HIV‑1-receptor binding is mediated by external Env gp120, which binds the CD4 primary 
on target cells. Then, a series of Env conformational changes occur that result in exposure of 
a transient binding site allowing the virus to interact with its co-receptor, usually the 
chemokine receptor CCR5 or CXCR4, to initiate another cycle of infection (figure 3A, B). 
HIV-1 gp120 consists of five conserved (C1-C5) and five extremely variable (V1-V5) 
domains. The conserved domains contribute to the core of gp120, while the variable 
domains (and numerous N-linked glycosylation sites) are located near the surface of the 
molecule. The gp120 is extensively glycosylated with N-linked glycan host derived 
carbohydrates. The role of these modification is to mask them and their micro-
heterogeneities form a perfect immunological shield that allow a decrease of the immune 
response against viral particles (Pancera et al., 2010) The presence of glycosylation sites in 
the V3 region seems to affect the viral tropism. Removal of the glycosylation site at position 
301 allows the chimeric virus to evolve to X4 phenotype (Pollakis et al., 2001). The removal 
of three amino acids on different glycosylation sites of gp120 from the laboratory strain 
X4R5 HIV89.6 tropism results in the loss of tropism for CCR5 (Yang et al., 2010). This 
phenomenon could be due to the unmasking of neighboring basic amino acids or the loss of 
negative charges located on the glycoprotein. Moreover, the number of glycosylations 
present on gp120 influences its secondary structure, which could alter the interactions 
between the V3 region and neighboring regions (figure 3F). The ability of some strains to be 
infectious and replicate even in the absence of V3 loop has been described (Cormier & 
Dragic, 2002)(Lin et al., 2007). The V3 region (35 amino acids) plays a significant role in the 
recognition and interaction with the cellular receptors of the target cell. This region also 
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contains at its extremity a highly conserved sequence of amino acids (GPGRAF). This 
pattern is surrounded by variable amino acids which alter the viral tropism through 
interaction of gp120 with the cellular chemokine CCR5 and CXCR4. The V1-V5 regions form 
exposed loops anchored at their bases by disulfide bonds (Teixeira et al., 2011). Crystal 
structure of gp120 shows that this protein is folded as a connection of four ǃ elements called 
“bridging sheet”with an inner and an outer domain (Kwong et al., 1998). The internal 
domain is a near point of contact with gp41 and the N and C-Term of gp120. In the native 
conformation, trimers are more stable due to the interaction with gp41 and V1-V2 loops. 
Oligomeric gp120 protein can adopt a conformation called 'closed' as in primary isolates 
resulting in masking the receptor binding site of CD4 in V1 and V2 regions  while gp120 of 
TCLA viruses preferentially adopt an 'open' shape thereby reducing its affinity for this 
receptor. Finally the interaction with CD4 gives rise to an open structure enabling the link of 
viral and cellular membrane and an exposition of the V3 loop (Roux & Taylor, 2007). 
 
 
Fig. 3. Schematic representations of HIV-1 envelope glycoprotein A) Glycosylations sites 
present on gp160 glycoprotein B) Structure of the gp120-gp41 glycoprotein envelope of HIV 
(Pancera, 2005). C, D, E, F are obtained by cryo-electron tomography C) Structure of an HIV-
1 gp120 core with intact gp41-interactive region D) 90° rotation of C placement of the gp120-
CD4 complex in the electron density map (light gray), residues involved in gp41 interactions 
are colored with blue (Pancera et al., 2010) E) Schematic representation of HIV-1 native viral 
spike. The glycoprotein is shown as a transparent framework and represents three gp120 
molecules non-covalently linked to three gp41. Epitopes of broadly neutralizing monoclonal 
antibodies on gp120 (red) or gp41 are labelled with arrows. The IgG1b12-binding surface is 
labelled yellow, and the bases of the variable regions (missing in this structure) are labelled 
blue, green, and pink. (F) The same model with the gp120 glycans shown in blue reveals the 
extensive glycosylation present as an antibody evasion mechanism on Env, and glycans 
implicated in BNMAb 2G12 binding are highlighted in white and labelled with an arrow. 
HIV-1, human immunodeficiency virus type-1; MPER membrane-proximal external region 
patterns obtained from the works of (Sattentau & McMichael, 2010).  
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CD4 receptor binding site 
The main receptor of HIV is the CD4 membrane glycoprotein. Binding to CD4 initiates the 
process of infection. Different models forecast the exact configuration of some regions of the 
gp120 protein whereas they all show clearly the important structural differences in the 
organization of the trimer between the free and the associated form with CD4. The CD4 
molecule binds with high affinity to gp120 protein (Klatzmann et al., 1984). The CD4 
binding site is composed of relatively conserved regions located between the two domains 
of gp120, and the ǃ inter-domains sheet. The contact areas are discontinuous in the native 
three-dimensional structure of protein. The CD4 binding domain is located in the D1 
domain of the CDR2 loop (Complementarity Determining Region 2), on the opposite side of 
HLA type II binding domain (Fleury et al., 1991). In this area, two residues, Phe43 and 
Arg59, are particularly important in establishing interactions with gp120 residues of the 
CD4 binding site (including Glu370, Trp427 and Asp368) (Tachibana et al., 2000). The affinity of 
CD4 to the envelope glycoprotein of HIV is highly variable depending on its quaternary 
structure (monomeric or oligomeric) and tropism. In addition, gp120 is conformationally 
flexible, the site of initial CD4 attachment is conformationally inert (Zanetti et al., 2006; Zhu 
et al., 2006; Roux & Taylor, 2007). 
Co-receptors of HIV 
The two main HIV co-receptors are the chemokine receptors CXCR4 and CCR5 (figure7). 
CXCR4 and CCR5 are ubiquitously expressed in immune cells. CXCR4 and CCR5 belong to 
the superfamily of receptors linked to G proteins and are characterized by a structure 
comprising an extracellular N-Term segment, seven transmembrane domains in helices, 
three extracellular loops or ECL, three intracytoplasmic loops or ICL (intracellular loop) and 
an intracytoplasmic C-Term segment. The N-Term segment and extracellular loops are 
responsible for receptor affinity for its ligand (Allen et al., 2007). 
The natural ligand for CXCR4 is the SDF-1 molecule (Stromal Derived Factor-1), a 
chemokine ǂ of CXC type (presence of two cysteines separated by one amino acid). As a 
ligand, it induces internalization of CXCR4 by a process of vesicle clathrin-dependent 
endocytosis, resulting to its degradation. CCR5 is the receptor of three chemokine ǃ of CC-
type (with two adjacent cysteines), all produced by CD8 T cells: RANTES (Regulated upon 
Activation, Normal T-cell Expressed and secreted), MIP-1ǂ and ǃ (Macrophage 
Inflammatory Protein-1). RANTES induces CCR5 internalization and is recycled to the cell 
membrane without being degraded. According to the coreceptor involved in HIV entry into 
the target cell, the virus is classified depending on its tropism. Thus, viruses use the CCR5 
receptor (expressed by monocytes, macrophages, activated T cells or memories and DC) are 
called 'CCR5-tropic' (or virus type 'R5') and those using the CXCR4 coreceptor (expressed by 
T cells, monocytes and DCs) are appointed, CXCR4-tropic '(or virus 'X4'). CXCR4 is the 
coreceptor identified as responsible for the entry of HIV in the lymphoid lineages adapted 
X4 viruses are also called 'T-tropic' or 'lymphocytotropic', whereas R5 viruses are called 'M-
tropic' or 'monocytotropic'. Some isolates are capable of using both CXCR4 and CCR5 
coreceptor and are referred as' X4R5' or ‘dual-tropic'. This classification has replaced an old 
classification based on the ability of the virus or not to induce syncytium formation (a 
reaction resulting in the cytopathic membrane fusion of several adjacent cells leading to the 
formation of a 'giant cell' multinucleate) at a T cell line (MT-2). It is now accepted that 
viruses using the CXCR4 coreceptor to enter target cells induce the formation of syncytia (SI 
virus like 'Syncytium Inducing virus') in contrast to viruses using exclusively CCR5 (NSI 
viruses for 'No Syncytium Inducing virus'). 
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2.3 Alternative receptors 
However, cells which not express the CD4 molecule on their surface can also be infected, at 
least in vitro. The CD4 is not the only molecule favoring infection by HIV-1. 
2.3.1 Interaction with Galactosyl-ceramide (α-GalCer) 
Surface molecules such as the -GalCer glycolipid or lactosylceramide sulfate, present on 
different tissues (brain, intestine, epithelium and cervix) are capable of binding to gp160 
protein V3 loop. These molecules can be considered as alternative receptors for HIV. The -
GalCer is a glycosphingolipid (GSL) most commonly involved in the interactions between 
cells lacking CD4 and HIV. It binds to the V3 region of gp120 (Harouse et al., 1995). These 
sequences form a conformational site exposed on the gp120 surface which interact with the 
galactose residue of GalCer. The affinity of gp120 to GalCer was higher than for other GSL 
(Long et al., 1994). Saturating the V3 area of gp120 with GalCer analogs can prevent the 
infection of CD4+ T cells and CD4- by HIV (Fantini et al., 1997). GalCer is also capable of 
binding to gp41 domain located in a 35 amino acids region containing the ELDKWA epitope 
(Alfsen and Bomsel, 2002). This interaction takes place only after fixation on gp120 and 
GalCer stabilization. The -GalCer/gp120 or gp41 interaction is also essential for viral 
particles transmission during endocytosis or transcytosis. The GSL are constituents of the 
lipid bilayer of the cell membrane and are associated with glycophospholipides (LPG) and 
cholesterol. This association form within the membrane microdomains distinct called “lipid 
rafts” (or 'rafts') (Simons and Ikonen, 1997). These lipid rafts traffic areas are preferred 
across the cell membrane for various pathogens or their toxins that use protein or lipid 
components of these micro-domains like receptors (Van der Goot & Harder, 2001). Lipid 
rafts are involved in the infectious cycle of HIV, particularly for the entry into target cells 
(Campbell et al., 2001). In the case of CD4-dependent infection and after fixation of the 
gp120 on CD4, an interaction between the central portion of the V3 region and the GSL 
would be essential to the establishment of the association between gp120 and coreceptors 
(Nehete et al., 2002). GSL present in lipid rafts can stabilize the attachment of the virus to the 
cell surface and to ensure migration of gp120-CD4 complex to a co-receptor. Rafts can move 
within the membrane and facilitate conformational change of gp120 leading to the insertion 
of the fusion peptide.  
2.3.2 Interaction with C-type lectins 
C-type lectins (CLR, C-type Lectin Receptor) are proteins that attach, with a calcium-
dependent way, the carbohydrated residues through their CRD domain (Carbohydrate 
Recognition Domain). They are particularly expressed on dendritic cells where they play a 
key role in capturing pathogens by binding carbohydrates present on micro-organisms 
(Weis et al., 1998). There are two categories of CLR: CLR's type I which exposed their N-
Term part outside the cell and the type II CLR with intracellular N-Term domain. The 
majority of CLR binds D-mannose, D-glucose or D-galactose and their derivatives. Four 
CLR type lectins have the ability to bind to gp120: MMR, MBL, DC-SIGN and Langerin.  
Lectin MMR (Macrophage Mannose Receptor, or CD206) is highly expressed by dendritic 
cells generated in vitro from monocytes but not expressed by those of blood. Macrophages 
are capable of transferring HIV to cells expressing CD4 using this receptor (Nguyen and 
Hildreth, 2003).  
MBL (Mannose Binding Lectin) is a CLR type I present in serum as a soluble form where it 
can bind to pathogens and initiate their attack by the complement system. It is capable of 
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binding to HIV through highly mannosylated oligosaccharides residues contains in the 
gp120 (Saifuddin et al., 2000).  
The CLR type II DC-SIGN (Dendritic Cell-Specific ICAM-3 Grabbing Non-integrin, or 
CD209), is expressed as tetramers in lipid rafts of immature dendritic cells (Cambi et al., 
2004). Its natural ligand is ICAM-3 (intercellular adhesion molecule-3 or CD50) also present 
on T cells which allow its interaction with dendritic cells (Geijtenbeek et al., 2000a; 
Geijtenbeek et al., 2000b). Like MBL, DC-SIGN binds mannose residues embedded into 
more internal patterns and more complex than MMR. DC-SIGN binds to Gp120 from many 
strains of HIV and SIV which harbor many oligosaccharides rich in mannose residues 
(Geijtenbeek et al., 2000b). Finally, Langerin (or CD207) is a CLR type receptor specifically 
expressed by Langerhans cells. Langerin is responsible for the formation of Birbeck granules 
(Valladeau et al., 2000) and contains a specific region which interacts with gp120 (Turville et 
al., 2002). 
2.3.3 Interaction with the α4β7 integrin 
It was recently demonstrated that gp120 activated form is also able to bind ǂ4ǃ7 integrin 
expressed on gut-homing T and B lymphocytes and CD4+ NK cells (figure4). A tri-peptide 
loop (Leu-Asp-Val) at the V2 loop, mimicking the binding motif of the natural ligands of 
ǂ4ǃ7, is involved in this interaction. This binding enables the formation of viral synapse 
through the activation of LFA-1 (Arthos et al., 2008). By this way, HIV-1 induces a massive 
depletion of gut CD4+ T cells which participate to the immune dysfunction in HIV patients. 
 
 
Fig. 4. Positions of all potential N-Glycosylation and ǂ4ǃ7 binding sites located in the V1/V2 
loop gp120  (Nawaz et al., 2011). 
2.4 Gp41 envelope glycoprotein  
The binding of gp 120 to CD4 and coreceptors permits its conformational changes and 
triggers the establishment of the fusion complex compounds by trimers of gp41 (figure6). 
(Salzwedel et al., 1999, Munoz-Barroso et al., 1999, Dwyer et al., 2003). Gp41 is the 
transmembrane domain of the entire envelope glycoprotein which anchors the viral spikes 
in the bilayer lipid membrane of viral particles and plays an important role in membrane 
fusion and cell entry. Gp41 is composed by 345 amino acids (512 to 856 of HIV-1 HXB2 
strain) with a molecular mass of about 41KDa. Gp41 presents an extracellular domain or 
ectodomain, a transmembrane domain or membrane spanning domain, and an 
intracytoplasmic domain (figure5). Gp41 sequences are clearly more conserved than gp120 
and also contain only four N-glycosylation sites on its ectodomain. These glycosylation sites 
are highly conserved and appeared to contribute to optimal viral replication efficiency 
(Johnson et al., 2001).  
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Fig. 5. Schematic representation of gp41 domains. Gp41 is divided in 3 regions. The 
ectodomain contains the fusion peptide (FP), a polar region (PR), N and C-terminal heptad 
repeat regions separated by an immunodominant region (NHR & CHR), a rich tryptophane 
highly conserved region (MPER), a transmenbrane region (TM) and an intracytoplasmic tail 
(CT) (Montero et al., 2008). 
Gp41 contains different domains involved in the fusion process of viral and host cell 
membrane. The N-Term hydrophobic region consist in the fusion peptide (512–527), a polar 
region (525-543) called the Fusion Peptide Proximal Region (FPPR) or Polar Region (PR), the 
N-Term heptad repeat (NHR or HR1) (546– 581) and C-Term heptad repeat (CHR or HR2). 
These regions are folded as ǂ-helix and linked by a loop called immunodominant loop (598-
604) containing a disulfide bridge. A highly conserved Tryptophan Rich Membrane 
Proximal Ectodomain/External Region (MPER) (660-683) is also present (Chan et al., 1997). 
Finally, the membrane spanning domain or transmembrane (MSD/TM) and the 
intracytoplasmic tail or C-tail are two other hydrophobic regions present at the C-Term 
portion of gp41 (figure5). A complete description of the whole molecule gp41 is not clearly 
defined. A crystallized intact trimer would be structurally definitive, but it’s seems that 
large regions appear to be in constant motion as part of the conformational masking defence 
of potential epitopes from Abs. It is widely assumed that the failure of Env-based vaccine 
candidates to date relates, in part, to the difficulty in generating soluble versions of Env 
proteins that faithfully mimic key structural features of native in situ Env. 
2.4.1 Fusion peptide (FP) 
The FP corresponds to the first N-Term domain of the gp41 ectodomain (figure5). FP is 
highly conserved among HIV-1 clades and other viruses. For example, GFLG is a pattern 
found among fusion peptides of different retroviruses such as HIV-1, HIV-2, SIV and HBV 
(Durell et al., 1997). A mutation in the GFLG alters the fusogenicity of the FP (Pritsker et al., 
1999). Other studies of HIV with truncated or mutated FP showed that it’s crucial to the 
fusion process and viral entry into host cells (Qiang et al., 2009). 
 
 
 
 
Fig. 6. Model of HIV entry pathway and gp41 conformational intermediates. Gp41 HR1 and 
HR2 regions are depicted in magenta and green, respectively (Miller et al., 2005). 
www.intechopen.com
 HIV-1 Glycoprotein Immunogenicity 
 
11 
FP is mostly hydrophobic (Del Angel et al., 2002). The substitution of glycine residues 
results in a fusogenicity decrease (Vanlandschoot et al., 1998). It has been suggested that the 
succession of FP glycines is involved in the oligomerization of fusion peptides, in the 
balance of amphipathicity necessary for membrane fusion and/or orientation of fusion 
peptides in the membrane (Delahunty et al., 1996). Recent studies showed that FP can also 
change its conformation according to the biochemical environment ((Buzon et al., 2005; 
Gordon et al., 2008). Solid-state nuclear magnetic resonance (MNR) spectroscopy (Zheng et 
al., 2006) confirmed that the FP oscillates from an ǂ-helical state in low concentration of 
cholesterol to the ǃ-strand form what reveals a high playing a crucial role during the viral 
fusion process. There are also controversies over the functional structure and the size of the 
FP it could have a different length and by the way a different sequence as 16 aa (Kamath 
and Wong, 2002), 23 aa (Delahunty et al., 1996; Gordon et al., 2002) or 33 aa (Pritsker et al., 
1999) . To date the native structure in prefusogenic and fusogenic state remains unravelled. 
 
 
 
Fig. 7. Interaction between critical sequences in NHR and CHR regions of gp41 fusion 
intermediate. Dashed lines between the NHR and CHR domains indicate the interaction 
between the residues located at the e, g and a, d positions in the helical spiral of NHR and 
CHR domains, respectively. The critical sequences in NHR and CHR include: GIV (residues 
547–549, red) is a determinant of resistance to T-20 in NHR region, LLQLTVWGIKQLQARIL 
(residues 565–581, green) is the cavity-forming sequence in NHR region, WMEWDREI 
(residues 628–635, orange) is the cavity binding sequence in CHR region; and WASLWNWF 
(residues 666–673, pink) is a partial tryptophan-rich sequence (Pan et al., 2010).  
2.4.2 N-heptad repeat (NHR) / C-heptad repeat (CHR) regions 
Adjacent to the FP is the first of two HR’s (N and C-HR, respectively) that play critical roles 
in the fusion activity of gp41 (figures5, 6). HR motifs contain a characteristic repeating 
pattern of seven residues (abcdefg). Amino acid sequence of these segments is composed of 
seven AA which occupy seven positions on the fusogenic structure forming a pattern. This 
pattern repeats 7 times hence the name seven-repeat (heptad repeat). In the CHR, AA in 
position “a” and “d” are generally apolar or hydrophobic and are crucial for stabilizing 
trimers (figures7, 8). The “e” and “g” residues in NHR frequently interact with residues in 
the “a” and “d” positions. Characteristic packing of the hydrophobic side chains as the HR 
in a helical configuration stabilizes the coiled-coil structures N-HR (aa 541-581). Two 
binding sites have been characterized which bind the CHR region (aa 610-683) through the 
residues “g” and “e” or the endogenous homotrimeric NHR region through the residues “a” 
and “d” (Bewley et al., 2002).  
A five-amino acid hydrophilic loop containing two cysteine residues with an intramolecular 
bisulfure bridge links the two HR regions together. These cysteines are highly conserved 
among retroviruses. It has been proposed that this loop creates a ‘knob-like’ protrusion in 
the TM subunit that permits packing in a cavity ‘socket’ in the surface subunit (figure6). This 
region is disordered in high-resolution studies of the gp41 ectodomain and has been 
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reported to lead to aggregation of the protein (Caffrey et al., 2000). Structures of pre-fusion 
forms of gp41 are undetermined. Nevertheless the crystal structure of gp41 and X-ray and 
NMR structures determines its 6Helix Bundle and final states this studies revealed that three 
NHR are folded into a central triple-stranded coiled coil of ǂ-helices, and three CHR are 
packed, anti-parallel, as ǂ-helix into the three channels of the coiled-coil (figures6, 7, 8A) 
(Chan et al., 1997). The inner-helical NHR trimer in the 6HB structures has been used to 
model the receptor-activated state of gp41 and to design several mimetics of the NHR 
coiled-coil that can potently inhibit fusion like the T20 or N36 peptides. This 6HB is 
thermally stable and can confidently be considered a final structure. The formation of 6HBs 
was originally accepted as being the process that brings the viral and the cellular 
membranes together and allows the aggregation of several activated Env complexes to form 
a pore, leading to the entry of the nucleocapsid into the cell (Markosyan et al., 2009). 
 
 
Fig. 8. Schematic representations of the six-helix bundle (6HB) in gp41 at the fusogenic state. 
A) Description of the six helix bundle: describes the N-(bright) and C-(dusky) heptad 
repeats that fold in an anti-parallel shape (hairpin). Three monomers of NHR form a -helix 
trimer in the central triple-stranded coiled coil and the C-HR region comes to bind the 
grooves of this structure to form the final state of 6HB. The link between the two heptad 
repeat regions is involved in the aggregation of this complex. (Weiss, 2003) B) Overview of 
depiction of a 6 helix bundle. Three NHR from each gp41 monomer form grooves and to 
complete the bundle three HR2 dock in them (Markosyan et al., 2009). 
 
Fig. 9. Schematic speculative representation of topological questions related to single-spike-
mediated fusion mechanisms. a,b) gp120 interacts with CD4 then with a co-receptor CR. The 
binding of the fusion peptide segment allows a changing of conformation and the HR 
regions form pre-hairpin shapes. c, d) Model where conformational changes undergo easily 
but require membrane breaks to form the 6HB. E, f), Second model where the membranes 
remain intact during the folding of gp41. CHR and NHR helix bind together and form the 
fusion pore. NHR, gold; CHR, red (Roux & Taylor, 2007). 
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2.4.3 The Membrane Proximal Ectodomain/external Region (MPER) 
The MPER segment or Membrane-Proximal External Region is bordered by HR2 region and 
TM segment of gp41 (figures5, 9). This region is rich in tryptophan residues and interacts 
with cholesterol in the lipid bilayer cell membrane playing an important role in the viral 
fusion process and infectivity of HIV-1 (Salzwedel et al., 1999). MPER seems to be involved 
in the early steps of viral fusion and syncytium formation (Munoz-Barroso et al., 1999). 
Mutations in MPER induce a decrease of the virus ability to cause syncytium formation in 
infected cells due to the inability to form the fusion complex (Zwick et al., 2001; Veiga and 
Castanho, 2007). MPER is highly conserved and represents a major target for therapeutic 
approaches. MPER sequence (663ELDKWASLWNWFNITNWLWYIK683) is the same in most 
HIV-1 strains and includes epitopes of 3 well described human broadly neutralizing 
monoclonal Abs as (ELDKWA) for the 2F5 and WF(N/D)IT for 4E10 and Z13 
(figure12)(Ofek et al., 2004; Zwick and Burton, 2007). MPER has also been described as ǂ-
helix or as an extenteded ǃ-turn. Recent studies have revealed that MPER adopts a helical 
form that is kinked and somewhat L-shaped and the segment that contains the epitope of 
4E10 is embedded within the bilayer lipid membrane (Sun et al., 2008; Franquelim et al., 
2011). The structure of the MPER in the context of lipids is well known, but the question of 
its native structure(s) on the cell surface in the context of gp41 remains open. 
2.4.4 Transmembrane (TM) or Membrane spanning domain (MSD) 
The TM region or MSD contains 25aa (aa681–705) is surrounded at its N-Term side by 
MPER and by the cytoplasmic domain at its C-Term tail (figures5, 9). This region is 
encrusted in the viral bilayer lipid membrane and anchors the gp41 into the membrane. This 
highly conserved region is composed mostly of neutral and hydrophobic AA (figure10). 
Two models have been proposed to explain the conformation assumed by MSD: a stable 
sloping -helical conformation and a metastable kinked curved conformation and the MSD 
seem to switches from one to another while conformational changes of the gp41 
(Gangupomu and Abrams, 2010). 
 
 
Fig. 10. AA sequence of HIV-1 membrane spanning domains: The consensus sequence of the 
HIV-1 MSD was generated by the alignment of the Env MSD sequences of all M and N 
groups HIV-1 isolates from the Los Alamos HIV database. The graphic shows the 
percentage of conserved residues among isolates from (Shang et al., 2008). 
The MSD contains two common features of lentiviral MSD, a basic charged residue Arg694 
buried in bilayer lipid membrane (Shang et al., 2008) and a very conserved motif 688GXXXG 
694 . The loss of this feature doesn’t affect the formation of glycoprotein Env trimers during 
the transport from the endoplasmic reticulum to the Golgi apparatus. However, it alters the 
membrane fusion and viral infectivity such as the loss of Lys681, Arg 694 or Arg705 (Shang et 
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al., 2008). The MSD or TM plays a very important role in viral fusion (figure9) (Miyauchi et 
al., 2010). Truncation studies on HIV-1 Env revealed that only 17 amino acid residues 
(Lys681-Ala697) are needed for a stable anchoring of the gp41 in the membrane and mediating 
cell to cell fusion (Yue et al., 2009). Small deletions (three amino acid residues) in the region 
between Arg694 and Arg705 showed normal cell to cell fusion, while larger deletions were 
more deleterious, suggesting that, the length of this region is more important than its AA 
sequence (Owens et al., 1994). Substitution of all leucine residues or two other highly 
conserved residues, Phe683 with Val687 AA residues in the helical core of MSD is critical for 
the fusogenicity of Env complexes and infectivity (Shang et al., 2008). 
2.4.5 The C-Term tail / intra cytoplasmic tail (CT/ICS) 
Lentiviruses, including HIV-1, have TM envelope (Env) glycoproteins with cytoplasmic tails 
(CT) that are quite long compared with those of other retroviruses. The gp41 CT is 
remarkably long and follows the MSD. CT is a hydrophobic region of 150 AA inserted into 
the plasma membrane (figure9A, 11) (Viard et al., 2008). The CT contains three regions 
called lentiviral lytic peptide and form amphipathic helices. The LLP1 and LLP2 regions 
have high hydrophobic properties. It have been admitted that the CT is entirely contained 
inside the cell or virion (Gallaher, 1987). Whereas it have been revealed that there are Abs 
directed to an epitope in the CT and some of them present neutralization properties on HIV 
virions (Cleveland et al., 2003; McInerney et al., 1999; McLain et al., 2001; Reading et al., 
2003). Then, since antibodies do not traverse the membrane and infectious virus are by 
definition intact, this suggests that part of the tail is exposed on the virion surface allowing 
antibody binding and neutralization, thus contrasting with the traditional intracytoplasmic 
location of the entire C-Term sequence of gp41 (Hollier & Dimmock, 2005). Studies have 
attempted to address this divergence between the old model of an exclusively 
intracytoplasmic tail and an alternative model with external segments of the CT, as the 
Kennedy peptide (aa731-752) (Kennedy et al., 1986) containing three patterns a conserved 
one 741EEEGGE746 and two others 747QDRDRS752 or 731PRGPDRPGRI740. At the early steps of 
the viral entry, CT is implicated in the regulating of the kinetics of fusion and in the ability 
of Env to promote syncytia (Edwards et al., 2002; Wyss et al., 2005). Mutational studies have 
revealed that long CT interacts with domains of HIV matrix like the p55 Gag protein during 
the budding and this interaction is required for the envelope incorporation into the virion 
(Dubay et al., 1992; Yu et al., 1993).  
3. Envelope glycoprotein immunogenicity 
HIV -1 patients generate strong Ab responses to the viral envelope glycoprotein. However, 
these antibodies are generally strain-specific or non-neutralizing what disable the immune 
system to install a protective or a preventive immune response (Kwong et al., 2002; Wei et al., 
2003). Most of the monoclonal antibodies raised against the env glycoprotein seems to be 
shaped by 1F7 (IgM) idiotypic dominance (Zhou et al., 2010). Evidence suggests that anti-HIV 
broadly neutralizing Abs requires high levels of somatic hypermutation and polyreactivity. 
However it is unclear if Abs without 1F7 idiotype also requires these characteristics to 
neutralize a broad spectrum of viral variants. It is also unknown whether BnAbs not 
expressing the 1F7 idiotype are any easier, or even possible, to induce by vaccination than 
idiotypic BnAbs, if the 1F7 idotype is suppressed (Parsons,M.S. et al., 2011). Genetic sequence 
variability created by its error prone reverse transcriptase and by host immune pressure lead 
www.intechopen.com
 HIV-1 Glycoprotein Immunogenicity 
 
15 
to the evolution of the HIV-1 into multiple subtypes or clades with circulating recombinant 
forms. A fundamental barrier to HIV-1 vaccine development lies with the unique properties of 
the virus to predominantly enter through mucosal surfaces, to target preferentially human 
CD4+ T cells, and to establish quickly a persistent reservoir of latently infected cells. Properties 
of transmitted (founder) viruses from mucosal transmission indicate that in 70–80% of cases, a 
single virus or virus-infected cell establishes productive clinical infection (Fischer et al., 2010). 
Such viruses typically exhibit C-C chemokine receptor type 5 (CCR5)-dependence. Mask 
functional envelope trimers needed to trigger efficient antibody response, and undergo rapid 
mutation as productive infection ensues (Goonetilleke et al., 2009; Keele et al., 2008). These 
viral properties narrow innate and adaptive immune pathways that can efficiently defend 
against HIV-1 entry and productive infection. Because of this global diversity (up to 35% in 
envelope gp120), it may impossible to design a single vaccine candidate that can induce potent 
effector immunity to multiple key antigenic determinants among worldwide circulating 
infecting HIV-1 strains. Although innate immune mechanisms contribute to HIV-1 control 
(Alter et al., 2007; Alter & Moody, 2010), it remains unclear whether recapitulating these 
responses with a vaccine will enhance protection against HIV-1 acquisition. 
 
 
Fig. 11. Schematic models of the HIV-1 CT. A) A total intracytoplasmic localization of the CT 
with one membrane-spanning ǂ-helix sequence (Traditional model). B) Alternative model 
with 3 MSD ǃ-sheets and an extracellular segment that bears the Kennedy peptide Adapted 
from (Steckbeck et al., 2010). 
3.1 Gp120 immunogenicity 
During HIV-1 infection, gp120-specific Abs are generated and some of them are directed to 
conserved sites on Env crucial to host receptor recognition or viral fusion (table 2) 
Conventional insight suggests that constant rather than variable regions of Env should be 
targeted by the immune system to elicit broad responses against diverse HIV strains. 
However, these regions were classified on single criteria as the sequence and for only a few 
virus strains (Zolla-Pazner and Cardozo, 2010). Whereas immunological and 3-D structural 
studies of Env have shown that these regions were flexible and variable to interact with 
other surface molecules thus explaining how Abs specific for some variable regions have 
neutralizing activity against diverse viruses. Although, gp120-specific Abs typically 
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recognize type-specific neutralizing epitopes located on variable loops (Davis et al., 2009) or 
recognize dominant non-neutralizing conserved epitopes in gp120 (Palker et al., 1987) or 
gp41 (Gnann et al., 1987). Inducing neutralizing antibodies that target these epitopes using 
rationally designed immunogens has, so far, been unsuccessful (Selvarajah et al., 2005; 
Selvarajah et al., 2008; Wu et al., 2010).  
This provides a rational basis for understanding the immunological cross-reactivity of many 
monoclonal Abs targeting the second (V2) and third (V3) variable loops of gp120, and the 
quaternary neutralization epitopes (QNEs) formed by V2 and V3. The glycan-rich outer face 
of gp120 is also the target of 2G12 broadly neutralizing mAb (Calarese et al., 2003; Huskens 
et al., 2007; Scanlan et al., 2002; Trkola et al., 1995). The V3 and the “bridging sheet” contain 
the binding site for co-receptor (CCR5 or CXCR4), but Abs against these targets are typically 
weakly neutralizing due to limited epitope exposure on native Env, and steric and kinetic 
restrictions post-CD4 engagement (Binley et al., 2004; Hartley et al., 2005; Reeves et al., 2005) 
 
 
Fig. 12. Epitope modeling of HIV-1 trimer-specific neutralizing antibodies. The above model 
is adapted from a recent cryoelectron tomographic structure of the HIV-1 trimer (Liu et al., 
2008; Schief et al., 2009). The crystal structure of the b12-bound monomeric gp120 core has 
been fitted into the density map (Zhou et al., 2007). The V1/V2 and V3 loops, which are not 
resolved in the structure, are represented as yellow and magenta ovals, respectively. The red 
structure located above the trimer is representative of a human IgG1 molecule. The 
approximate locations of the epitopes targeted by the existing NAbs are indicated with 
arrows. Carbohydrate chains are shown in blue, and the oligomannose cluster targeted by 
mAb 2G12 is shown in orange (Walker and Burton, 2010) 
3.1.1 Receptor-binding sites 
Binding of gp120 to CD4 results in gp120 conformational changes that expose the binding site 
for a secondary co-receptor, which is either of the chemokine receptors CCR5 or CXCR4 
(Sterjovski et al., 2011). Crystallographic and biochemical studies of gp120 have provided 
valuable insights into mechanisms involved in CD4-binding and CD4-induced conformational 
changes that result in formation and exposure of the co-receptor binding site (Huang et al., 
2005; Myszka et al., 2000). The unbound gp120 core consists of a highly conserved inner 
domain, which faces the trimer axis, and a heavily glycosylated, outer domain, which is mostly 
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exposed on the surface of the trimmer (Kwong et al., 1998; Teixeira et al., 2011; Zolla-Pazner 
and Cardozo, 2010). CD4 binding site represents the encounter of three separate regions via 
their surface-exposed residues. These regions are distributed over 6 segments of gp120. These 
regions include the ǂ-helices of the inner domain, the CD4-binding loop of outer domain, and 
the ǃ20–ǃ21 ribbon, that incorporate the gp120 bridging sheet, which is a structural element of 
gp120 formed after CD4 binding that is involved in co-receptor binding. Otherwise, 
thermodynamic and structural analysis of the interaction between gp120–CD4 showed 
evidence of a structured CD4-binding pocket on the unloaded gp120, and that CD4 binding 
site elements that influence gp120–CD4 affinity are formed from conformational alterations 
that occur after gp120 has encountered CD4 (Kwong et al., 1998; Myszka et al., 2000). All these 
structures occur in the very early steps of the recognition (tropism) and anchorage process and 
provoke broad immune response. However, Abs remains interesting due to their large 
capacity to neutralize HIV-1 (table 1). The antibody IgG1b12 recognizes an epitope that 
overlaps the binding site of gp120 to the CD4 receptor. Several antibodies specific of the CD4 
binding site have been described by several teams as the 15th, F105, F91, 1125H, 21H, 654-30D 
and Fab b6. All these antibodies show responsiveness to monomeric gp120 from different 
isolates of HIV-1 while this response disappears with trimeric gp120 which is present on the 
viral envelope spikes. Only the b12 antibody binds these two forms, and neutralizes many 
strains of HIV-1 (Zwick et al., 2003). Recently, the VRC01 Ab has been identified by screening 
of sera from infected individuals. It could be detected with high proportion and titers in 
patients. VRC01 Ab has been mapped to the CD4 binding site of gp120 (Wu et al., 2010; Zhou 
et al., 2010). In these studies it was observed that among 190 circulating HIV-1 isolates tested 
for sensitivity to VRC01, 173 were neutralized and only 17 were resistant. A structural analysis 
of these 17 resistant isolates by threading their sequences onto the gp120 structure showed 
important variations in the V5 region. However, the low VRC01 resistance frequency suggests 
that VRC01 use a recognition mechanism that allows binding despite V5 variation. Study of 
VRC01 interaction with V5 shows that VRC01 recognition of V5 is different than CD4. The V5 
loop fits into the gap between heavy and light chains. Interaction with the more conserved 
residues at the loop base is sufficient for the VRC01 activity independently of variation in the 
top of the V5 loop.  
Neutralizing Abs directed against CD4 binding site have been recently compared (Pietzsch 
et al., 2010). Around 30% of high titers of broadly HIV-neutralizing Abs expressed by 
memory B cells in HIV+ patients recognize one or more “core” epitopes that were not 
defined. Some of them recognize the 474DMR476 motif on the gp120 which is conserved in 
different strains and its mutation alters the viral fusion process. For example, HJ6 exhibit a 
breadth neutralizing activity comparable to, and could be considered as complementary to 
b12. HJ16 also showed selective neutralization (Corti et al., 2010). 
3.1.2 CD4-induced region 
The receptor-binding structures of gp120 are conserved among diverse viral isolates and 
represent functionally constrained regions that might serve as targets of broadly 
neutralizing antibodies. However, structural evidence suggests that, within functional spike, 
the CD4-binding site (CD4bs) is a recessed pocket and the co-receptor-binding site (CD4-
induced region) is either not formed or not exposed until gp120 engages CD4 on target cells 
(Kwong et al., 1998). Numerous Abs were described for their binding to the CD4-induced 
site and the most interesting by their breadth neutralizing capacities are the 17b, X5, m18, 
and m14 which all contains long H3s playing a major role in their mechanism of binding 
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(table 1). The H3s region of X5, m6 and m9 appear to be very flexible and highly potent to 
neutralize the virus (Wen et al., 2010; Zhu et al., 2006) 
3.1.3 V1/V2 regions 
The V1/V2 loops are less investigated even if several studies have shown that the V1/V2 
domain of the HIV-1 gp120 envelope protein is involved in viral tropism during infection. 
V1V2 region interfere by masking conserved neutralizing epitopes, in the conformational 
changes occurring after co-receptor binding. 
As V1/V2 domain is highly glycosylated, numerous studies have determined the influence 
of carbohydrates on neutralizing antibodies production. As an example, mucosal secretory 
IgA from parotid saliva and also seric IgG from seropositives present differences in their 
neutralization properties in fuction of the clade and glycosylation state. (Granados-Gonzalez 
et al., 2009) 
 
 
Table 1. Main HIV-1 Env-specific neutralizing human monoclonal Abs. 
3.1.4 V3 region 
The b12 (CD4bs) and 2G12 (glycan) epitopes are presently the most attractive targets for 
vaccine design owing to their highly conserved nature. Although other sites seems present an 
interest in the immune response to gp120 as epitopes in the V3 region. This region is 
recognized by an antibody called 447- 52D (table 1) (Dhillon et al., 2008). Its core epitope is the 
Gly-Pro-Gly-Arg (GPGR) motif which is located at the center of the V3 region. This recognition 
is altered with the substitution of AA at the N-Term segment of the V3 region (Rosen et al., 
2005). This Ab neutralize both X4 and R5 primary isolates, making it one of the most effective 
anti-V3 Ab. X-ray crystal structure of 447- 52D in complex with a V3 peptide indicates how 
this antibody may have the capacity to neutralize more clade B viruses than other anti-V3. 
Since the binding interaction between the antibody and the peptide is mediated by main chain 
contacts, which enlarges the ability of the antibody to recognize a variety of V3 sequences 
(Stanfield et al., 2004). The only side-chain interactions are with the Pro and Arg-residues in 
the GPGR sequence; the side chains from both residues form extensive interactions with 
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residues in the Ab combining site. The side chain of the Arg residue in the GPGR sequence is 
oriented in the opposite direction in the 447-52D complex relative to its orientation in the other 
complexes with anti-V3 antibodies and V3 (Binley et al., 2004; Rosen et al., 2005). However, 
exposure of the V3 region during infection seems to occur exclusively in the context of gp120 
oligomer on the virus and may be influenced by the presence of glycan moieties. Given these 
caveats, the V3 region may be a target that only yields antibodies with restricted neutralizing 
ability. It is worth noting here that a 447-52D equivalent has not been identified so far for non–
clade B viruses. A novel human monoclonal Ab HGN194 was isolated from memory B cells of 
a long-term non-progressor infected with a HIV-1 clade AG circulating recombinant form 
(CRF). This Ab recognizes a conformational epitope in the V3 and neutralizes all tier 1 viruses 
which are relatively neutralization-sensitive but only 11% of the tier 2 viruses tested. Tier 2 
strains are more difficult to neutralize and reflect the majority of primary HIV-1 isolates. 
(Watkins et al., 2011) After massive immunization in Rhesus monkeys with the IgG1HGN194, 
the authors describe the absence of virus reservoirs after HGN194 was cleared. HGN194 seems 
to be an interesting cross-clade Nabs. 
3.1.5 Impact of glycosylations 
HIV uses glycans to occlude Ab epitopes on gp120. Around 50% of the molecule is covered 
with carbohydrates that render the underlying protein surface masked from the immune 
system and inaccessible (figure12). The virus can also shift the locations of its glycans in vivo 
(Nawaz et al., 2011). These observations gave a non static model called evolving glycan-
shield model by which, through the continuous repositioning of its N-glycosylations 
positons, HIV is able to escape from a specific neutralizing Ab response. Thus, the 
developed resistance is not a comprehensive one but, instead, a specific adaptation to the 
particular Ab response in each infected individual (Wei et al., 2003). In addition to being 
involved in blocking neutralizing Ab responses, glycan repositioning also may compensate 
for conformational changes in the envelope glycoprotein caused by localized AA changes 
directly related to virus escape from neutralizing antibody. The works of Trkola led to the 
characterization of the human monoclonal Ab 2G12 directed against the envelope 
glycoprotein gp120 of HIV-1. This antibody recognizes clustered ǂ1 → 2-linked mannose 
residues on the distal ends of oligomannose sugars located on the carbohydrate-covered 
silent face of the gp120 outer domain. It confers neutralizing activity in vitro on T cells 
infected with HIV-1 primary isolates from clade A or B. This study has demonstrated the 
ability of 2G12 to induce an immune response as "antibody-dependent cellular cytotoxicity 
ADCC" directed against infected cells or by activation of the complement system (Trkola et 
al., 1996). The epitope of 2G12 is described as a dependent structure of N-glycans in the C2, 
C3, V3, V4 and C4 regions of gp120. Other studies have described that the epitope 
recognized by monoclonal antibody 2G12 contains mannose type glycans at multiple sites of 
N-glycosylation (Calarese et al., 2003; Scanlan et al., 2002). This is not aware that the 
glycosylated epitopes contain microheterogenities at various carbohydrates which can lead 
to an escape from immune response. Only deletion of N392 glycosylation site is sufficient 
for decrease drastically 2G12 activies, which may explain the emergence of new strains viral 
resistance (Huskens et al., 2007; Scanlan et al., 2002). 
3.1.6 Quaternary neutralizing epitope 
Quaternary epitopes are formed by interactions between proteins during multimerization. It 
is as a result of such reorganization that many proteins (such as enzymes and the trimeric 
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gp120 spike of HIV‑1) carry out their physiological function. An Ab that reacts with a true 
quaternary epitope will not interact with the individual monomeric subunits. Monoclonal 
antibodies mAb2909 and PG16 (figure 14), react with the trimeric form of gp120 on the 
surface of HIV‑1 virions or env‑transfected cells but not with monomeric gp120 (Gorny et 
al., 2005; Walker et al., 2009). However, some Abs that react with quaternary epitopes binds 
preferentialy the trimers rather than monomeric subunits. This seems to be true for the 
monoclonal antibody PG9. Trimerization can result in changes in quaternary structure 
within individual subunits or through reorientation of the subunits against each other, so 
regions contributing to the quaternary epitope can be inter-molecular (trans) or 
intra‑molecular (cis). Recently, a human mAb (mAb 2909) (figure 14) has been described to 
bind to a quaternary structure only on virion but not to soluble monomeric gp120 (Changela 
et al., 2011; Gorny et al., 2005). It has been discovered by immortalization of PBMC from 
HIV 1 patients asymptomatic and drug-naïve (Gorny et al., 1991). It demonstrates a high 
neutralizing activity for primary isolate such as SF162 (picomolar concentrations) and 
specificity for a complex epitope consisting of V2, V3, and the CD4 binding site that is 
present exclusively on the surfaces of intact virions but not on soluble viral proteins (Gorny 
et al., 2005). The neutralizing activity of MAb 2909 against pseudovirus SF162 is 750- to 
100,000-fold more potent than those of other well-characterized. The occurrence of mAb 
2909 suggests the possible existence of additional Abs that are oligomer-specific. Such Abs, 
in contrast to mAb2909, may possess broader neutralizing activity.  
Moreover, two potent broadly neutralizing monoclonal antibodies, PG9 and PG16, have 
been discovered recently both targeting highly conformational, discontinuous epitopes 
involving the V2 and V3 loops (Walker et al., 2009). These antibodies have been 
characterized after a large screening of 1800 sera from HIV- and HIV+ donors from all over 
the world (Thailand, Australia, and United Kingdom etc). Only donors that exhibit broad 
and potent neuralizing serum activity were selected. Analysis of the antibody variable genes 
revealed two pairs of somatic variants, each one contained long, heavy-chain 
complementaritydetermining region 3 (CDRH3) loops (PG9 and PG16). Long CDRH3 loops 
have been previously associated with polyreactivity. PG9 and PG16 are somatically related 
and appear to be derived from the same recombination of heavy and light chains. The both 
Abs recognize a site on gp120 composed of elements from the V2 and V3 variable regions. 
Despite the vaunted diversity of the HIV-1 gp120 envelope and the even higher sequence 
variability in the V2 and V3 regions (Walker et al., 2009), neutralization assays indicate that 
the recognized epitope is conserved in 70 to 80% of circulating viral isolates. Neutralization 
by PG9 correlates strongly with that of PG16, indicating that these Abs recognize a common 
HIV-1 epitope. This suggests that a common surface of the paratope on PG9 and PG16 
might be involved in recognition of HIV-1. Substantial differences in sequence are found 
between PG9 and PG16 (Doria-Rose et al., 2010; Pancera et al., 2010). 
3.2 Gp41 immunogenicity 
Gp41 is largely occluded by quaternary interactions within native Env (Sougrat et al., 2007; 
Zanetti et al., 2006; Zhu et al., 2006). During the fusion process, different gp41 regions are 
exposed and elicit while the changing of conformation due to the intercation with gp120 
antibodies. Some of them are very essential and present interesting capacities to block the 
infection and neutralizing the virus. The neutralizing Abs 2F5, Z13e1 and 4E10 directed 
against the membrane-proximal external region (MPER) in the C-Term portion of the gp41 
ectodomain can bind Env and block a late stage of fusion (table 1) (Nelson et al., 2007; 
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Stiegler et al., 2001; Dimitrov et al., 2007; Zwick et al., 2005). Despite great efforts, high 
neutralizing Abs titers against any of the conserved sites on Env have not yet been elicited 
(Kim et al., 2007; Phogat and Wyatt, 2007). 
 
 
Fig. 14. Conserved and variable residues in the V1, V2 and V3 loops of gp120. A, b, d) 
Sequence logo describs the AA conservation pattern across a multiple alignment of many V1, 
V2 and V3 loops. The height of the letter indicates the degree of conservation of the most 
common amino acid at that position. Data obtained from the Los Alamos National Laboratory, 
New Mexico, USA. AA are colored according to their chemical properties. C) AA positions 
and sites of glycosylation that are implicated in binding of the V2‑specific monoclonal Ab 
697‑D and the Quaternay Neutralizing epitopes‑specific monoclonal Abs PG9, PG16 and 2909 
are mapped onto a schematic illustration. Square brackets indicate more than one commonly 
occurring AA at a single position. The individual sites associated with binding of each single 
Ab are distributed throughout the V1–V2 primary sequence linearly but, in 3D space, must 
group into one or a few overlapping epitopes (adapted from (Zolla-Pazner and Cardozo, 2010) 
3.2.1 Polar region (PR) 
Only one study described PR-specific Abs in HIV-1+ patients. However, these Abs remains 
poorly neutralizing (Buchacher et al., 1994).  
3.2.2 N-Heptad Repeat region 
Cross-reactive antibodies to the NHR have been detected in HIV-1-positive sera, indicating its 
immunogenic characteristics (Poumbourios et al., 1992). Moreover, the D5 NAb was generated 
from a native single-chain variable fragment library. D5 has been shown to bind to the NHR 
trimer and, like the T-20 peptide, inhibits the assembly of the fusion intermediate in vitro 
(Miller et al., 2005). Those studies indicate the potential of the inner NHR trimer as a target for 
vaccine design. D5 was derived from B cells of HIV-naive subjects and has not been subject to 
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extensive somatic hypermutation, with only seven non-complementarity-determining regions 
(CDR) amino acid changes from germline sequences (four changes in VH and three in VL). 
Unlike b12, 2F5, and 4E10, D5 does not have an atypically long heavy chain CDR3 region. 
Unlike 2G12, D5 does not require a ‘‘domain-swapped’’ structure for neutralization. Unlike 
X5, D5 retains antiviral activity against primary HIV isolates when converted to an IgG1 
format. Finally, and most importantly, D5 was elected by binding to IZN36 and 5H which are 
synthetic antigens with well defined structures mimicing the 6 helix bundle structure. In 
addition, new NAbs with limited potency against the NHR trimer of HIV-1 have been isolated 
by screening phage-display library (Nelson et al., 2008). Ag-binding and monoclonal Ab-
competition experiments using 8K8, DN9 and D5 strongly suggest that the epitopes of 8K8 
and DN9 are more closely related to each other than to that of D5. Although, D5 has a 
preference to bind NHR mimetics in the absence of CHR peptide thus  indicating a significant 
cross-reactivity of D5 with immobilized 6-Helix (Luftig et al., 2006; Miller et al., 2005),. 
Similarly, C34 HR2 peptide competes efficiently with 8K8 and DN9 binding to immobilized 
NHR mimetics (e.g. 5-Helix and IZN36), but not with D5. Another antibody, Fab 3764, has 
been shown to bind to the NHR region with the same efficiency on free (N35CCG-N13) or 
interacting with CHR peptide in the form of a 6-Helix Bundle (Gustchina et al., 2007; 
Gustchina et al., 2010). Further more absence of detectable cardiolipin reactivity with 8K8 178 
170–183 suggests that autoreactivity, at least to cardiolipin  cannot explain the weak titers of 
8K8-like Abs in the rabbits (Haynes et al., 2005; Scherer et al., 2007). Three-dimensional 
structural informations of the mAb-mimetic complexes may be used to better predict the 
accessibility to the NHR on fusogenic gp41 for prospective next-generation Abs. Recently, the 
HK20 gp41-specific antibody was obtained from immortalized memory B cells of an HIV-1 
infected individual (Corti et al., 2010). This Ab targets the conserved hydrophobic pocket in 
HR1. Crystal structure of HR1-specific human mAb HK20 in complex with 5-Helix shows that 
HK20 binds to the same region recognized by D5 but differs significantly in the contact sites 
and shows a role for somatic mutations in affinity maturation (Luftig et al., 2006). These 
aspects influence both potency and breadth of neutralization, which are higher for HK20 
compared to D5 and depend on somatically mutated residues. In addition, we show that in 
case of HK20 the scFv is at least 15-fold more potent in neutralization than IgG, consistent with 
a limited accessibility to the target site. The gp41 footprints of HK20 and D5 and the global 
structural principles employed by both antibodies are similar. 
3.2.3 Immunodominant loop  
This region located between the two heptad repeat region N-HR and C-HR was identified 
during serum-mapping studies (reviewed in Girard et al., 2006; Montero et al., 2008). Even if 
the response to this region is very frequent most of the Abs elicited do not present 
neutralization capacities but instead shown enhancement of infection (Robinson et al., 1990). 
Only one MAb (clone3) neutralize T-cell laboratory adapted viruses from clade B and three 
primary isolates from group O (Ferrantelli et al., 2004). 
3.2.4 C-Heptad repeat region (C-HR) 
Considering that MPER is not included in C-HR, no CHR-specific Ab has been described. 
The poor immunogenicity of this region may be attributed to its lack of exposure on the 
surface of the native virus and is exposed only if gp120/CD4 interaction occurred. This 
region is probably masked by gp120 (Nyambi et al., 2000; Pietzsch et al., 2010). 
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3.2.5 Fusogenic 6 helix-bundle form 
The gp41 TM subunit, which anchors the spikes in the viral envelope, maintains their 
trimeric organization, and plays a major role in fusion of the virus and host cell membrane 
through its hydrophobic N-Term fusion peptide and a fusion active hairpin structure 
involving the HR that can fold into a six-helix coiled-coil bundle. This pattern plays an 
important role in both the early and late stages of the membrane fusion (Chan and Kim, 
1998; Johnson et al., 2001; Liu et al., 2005; Lu et al., 1995; Munoz-Barroso et al., 1998). This 
process can also participate in the formation of the fusion pore through direct protein-
membrane interactions (Munoz-Barroso et al., 1998; Shnaper et al., 2004). Different studies 
have shown the immunogenicity of the fusogenic complex and describe Abs direct against 
this structure (Gustchina et al., 2010; Opalka et al., 2004; Vincent et al., 2008). Authors were 
confronted to the difficulty of the construction of a native form of the fusogenic complex 
with 6 helix-bundle and used a five helix-bundle (Gustchina et al., 2010) or synthetic peptide 
that mimic the N-HR like (peptide N36) or mimic C-HR (peptides C34 or T20). Abs directed 
against the complex do not always recognize the HR1 or HR2 individually. The Abs  have 
shown low neutralizing activity excepted in one study with Nabs against primary isolates 
(Vincent et al., 2008),  and the work of Gustchina et al., with a monoclonal antibody Fab 3674 
that neutralize diverse laboratory-adapted B strains of HIV-1 and primary isolates of 
subtypes A, B, and C (Gustchina et al., 2007). When gp41 switches from the native 
conformation to the fusion structure, there are probably several intermediate structures, 
which can be a target for Abs. Several studies indicate that the prehairpin intermediate state 
is accessible to Abs and that the access is not restricted (Louis et al., 2003). Therefore, the 
gp41 6-HB core may serve as an attractive target for development of anti-HIVmolecules. 
3.2.6 MPER (membrane-proximal external region) 
The Membrane Proximal Ectodomain Region contains the epitopes of three broadly 
neutralizing Abs, 2F5, 4E10, and Z13 (Buchacher et al., 1994; Zwick et al., 2001) (figure 15). 
MPER is not highly immunogenic like the N-HR, ID loop or the gp120. Specific anti-MPER 
Abs present in natural infection are not as broadly neutralizing as 2F5, 4E10 (Braibant et al., 
2006; Muhlbacher et al., 1999). Both 2F5 and 4E10 neutralize a broad range of both 
laboratory adapted and primate isolates of HIV-1 (Mascola et al., 2000; Stiegler et al., 2001). 
2F5 is the most potent NAb, whereas 4E10 neutralizes a broader range of HIV-1 isolates, as 
shown by pseudovirus studies using an extensive panel of Envs derived from primary 
isolates (Binley et al., 2004). The 2F5 Ab could also be detected at low level in the sera of HIV 
long term progressors (Braibant et al., 2006). The frequency of seroreactivity to MPER is 
about 56% in 50 HIV-1-positive subjects. Most of the Abs are specific for the C-Term region 
of the ELDKWA sequence just preceding the 2F5 epitope. In addition, more than 30% of sera 
were reactive to the ELDKWA 2F5 epitope. Furthermore, serum reactivity against an MPER 
peptide (aa 642 to 673) in patients could be correlated to the recognition of infected T cells 
and to CD4 cell counts (Muhlbacher et al., 1999). There is a possibility that NAbs against 
MPER are present in low titers or with low affinities in serum that they are not sufficiently 
neutralizing to inhibit HIV-1 infection and are therefore undetectable in neutralization 
assays. However, recent studies using chimeric pseudoviruses with epitopes in a context 
more closely related to the MPER structure (figure 15B) suggest that MPER-specific NABs 
are relatively rare or absent during natural infection. Moreover, the fact that new NAbs are 
mapping to a different region in MPER than 2F5 and 4E10 provides hopes by suggesting 
that vaccine-induced neutralizing antibodies are achievable (Haynes and Montefiori, 2006; 
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Li et al., 2006). To date, the lack of broadly neutralizing activity shown by MPER binding 
sera could be due to low titers or absence of NAbs. This issue of quantity versus quality has 
not been fully resolved but has significant implications for vaccine design.  
 
 
Fig. 15. Different representations of MPER interaction with 2F5 4E10 and Z13 Abs A) 
Schematic diagram of HIV-1 gp41. FP, fusion peptide region; NHR and CHR, N- and C-
terminal-helices of heptad repeat, respectively; and TM, transmembrane domain. The 
minimal peptide epitopes are indicated for 2F5 (blue), Z13e1 (green), and 4E10 (magenta). B) 
A simple model of env including MPER and TM based on 3D structural features of HIV-
1/SIV-1 trimeric env and the NMR structure of the HxB2 MPER in a virion mimic surface 
(blue plane). N674 rather than D674 is shown. C) Artistic rendering of MPER orientation 
changes induced by 4E10, 2F5, and Z13e1. Unbound MPER peptides (yellow tubes) are 
immersed in the lipid bilayers (light green panel). Red, blue, and green tubes represent the 
membrane orientation of schematic MPER segments in complex with 4E10, 2F5, and Z13e1 
(gray surface area). Several key binding residues positions are indicated before (yellow) and 
after (purple) antibody binding (Song et al., 2009). D) Hypothetical model of the MPER 
(DKWASLWNWFDITNWLW) and the 2F5, Z13e and 4E10 cores epitope with the core 
residues colored in yellow, green and violet, respectively described by (Nelson et al., 2007). 
As said before 2F5 Ab has broad neutralizing activity. In animal models it could interrupt 
the mucosal transmission and confers protection against SHIV infection (Mascola et al., 
2000). The 2F5 antibody was isolated from human immortalized B cells. It recognizes an 
epitope lying between glutamic acid 662 and alanine 667 (ELDKWA). Studies have shown, 
for expression library and protection against proteases, that this epitope is wider 
(EQELLELDKWASLWN). By addition of a leucine at each side (LELDKWASL), the affinity 
for its epitope is increased by more than 2000 times (Ofek et al., 2004; Parker et al., 2001; 
Tian et al., 2002). In models that study the involvement of the viral membrane using POPC 
(1-oleyl-2-palmolityl-sn-glycero-3-phosphocholine) and POPC/cholesterol in the 
recognition and binding to its epitope, it has been shown that 2F5 does not  interact with the 
membrane before fixation (Veiga and Castanho, 2006). In the absence of an hydrophobic 
environment, 2F5 and 4E10 are unable to bind to MPER (Ofek et al., 2004). This study 
demonstrate that the recognition of 2F5 and 4E10 epitopes depend on their integrity and 
conformational context. Recently, it was shown that the binding of 2F5 causes peptide 
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docking on the membrane and increase the ability of the Mab to be intrusive (Franquelim et 
al., 2011). The 2F5 induces a confined local disorder in the membrane which can promote the 
exposure and interaction with gp41. However, the role of the presence of lipids in 
recognition of epitopes during the membrane fusion has not yet been clearly elucidated. The 
2F5 epitope contains a -turn conformation and antigen which is presented in a similar 
context may better mimic the epitope and consequently improve the binding of this Ab 
(Tian et al., 2002). Several difficulties rise to make a stable immunogen, flexible and 
mimicking faithfully the MPER in a native conformation sported during the steps of 
rapprochement and viral fusion process. Moreover, the polyspecificity of 2F5 and 4E10 and 
autoreactivity by binding to cardiolipin  could explain the low activity of these antibodies in 
vivo as the immune system deplete all B cells which produce auto-reactive Abs (Haynes et 
al., 2005).  
Another promising MPER-specific Ab (4E10) was isolated from B cells of HIV patients. It 
binds a deeper epitope in the MPER and presents neutralizing abilities. The 4E10 is highly 
protective against infection with primary isolates and laboratory strains of HIV-1. The 4E10 
binds to a highly conserved linear epitope on MPER 671NWF (D/N) IT676 (Zwick et al., 2001). 
Crystallographic structures of the epitope have been characterized and form a large helical 
shape with all the important AA on the same side of the helix (Hager-Braun and Tomer, 
2005)( figure 15D). The antigen reacts only with residues of the base and the center of the 
loop of CDR H3. However much of this loop is not involved in its binding to the antigen. 
The top of the loop of CDR H3 of 4E10 and this residue is removed from the apolar binding 
site epitope which suggest a possible interaction with the membrane of the virus. Structural 
models predict that the formation of the epitope of 2F5 and 4E10 would be highly 
dependent on the presence of a membrane. The affinity of 4E10 increases in the presence of 
lipids (Lorizate et al., 2006). The W672, F673, T676 residues seems to be crucial for 4E10 binding 
since their substitution by alanine residues reduce drastically the affinity (Brunel et al., 
2006). The sequence 671NWFDITNWLWYIK683 is optimal for 4E10 recognition. In resistant 
strains, the pattern NWF(N/D)IT indicate that the 4E10 epitope  is more complex and would 
be even discontinuous (Hager-Braun and Tomer, 2005). Mass spectrometry studies reveal 
that 4E10 binds to the N-Term of gp120 and gp41 on the native conformation (Stiegler et al., 
2001). It has been suggested that the pattern NWF (N/D)IT forms a cryptic epitope 
accessible only during the intermediate stages of the merger. It seems that 4E10 has higher 
affinity to the membrane than 2F5 and that unlike 2F5, 4E10 promotes peptide extraction 
from the bilayer lipid membrane (Franquelim et al., 2011). The 4E10 Ab has also a 
polyspecificity for autoantigens as histone or DNA in systemic lupus erythematosus.  
Several in vivo pharmacokinetic studies and phase I/II clinical trials phases I and II with 
combination of 4E10, 2F5 and 2G12 showed that these three Abs are able to maintain 
undetectable viral load in patients where the infection has been suppressed by antiviral 
therapy (Joos et al., 2006). These studies also showed that 4E10 administration is not highly 
immunogenic with rare IgM against 4E10 but no IgG. Clearance and half-life of 4E10 are 
identical to those of other classical therapeutic Abs.  
One other described MPER-specific Ab is the Z13 Fab. This Ab derived from an expression 
library recognizes an epitope located on the C-Term of 2F5 epitope and which overlaps 4E10 
epitope. The epitope of Z13 is centered around the sequence 671NWFDIT676 but this would be 
dependent on the conformation of this motif and changes such as N-glycosylation of 
asparagine (D) 674 or exposure to a native protein (Zwick et al., 2001).This Ab is able to 
neutralize weakly several clades such as B, C and D.  
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3.2.7 The C-Term tail 
The external tail loop within the CT of the gp41 TM subunit of the HIV-1 envelope protein 
comprises approximately 40 AA, and within are 18 AA (734PDRPEGIEEEGGERDRDR 751) 
including three interesting regions. The antigenicity of this segment of the CT is very 
complex, and changes according to the biological context of gp41 (Reading et al., 2003). The 
Kennedy sequence, 731PRGPDRPEGIEEEGGERDRDRS752, is exposed on the outer surface 
(Kennedy et al., 1986). It was observed that 3 epitopes 734PDRPEG739, 740IEEE743, 746ERDRD750 
are mostly recognized in the Kennedy sequences (Chen et al., 2001; McLain et al., 2001). 
Kennedy-specific NAbs could be elicited in different conditions of exposure.  
The 746ERDRD750 epitope is exposed constitutively and does not require contact with cell 
receptors or an elevated temperature (Cleveland et al., 2003). 734PDRPEG739 is recognised by 
the non-neutralizing Ab C8, 740IEEE743 by the non-neutralizing Ab 1575 (Abacioglu et al., 
1994), 746ERDRD750 by the non-neutralising Abs 1577 and 1583 (Vella et al., 1993), and the 
neutralizing EPES (epitope purified and ERDRD specific) and SAR1 antibodies. EPES and 
SAR1 Abs were both obtained by immunisation of mice with cowpea mosaic virus (CPMV) 
chimeras expressing short, ERDRD-containing gp41 sequences. EPES is the only Kennedy-
specific polyclonal IgG described to have a strong neutralizing activity against primary 
isolates. It was also shown that some of the IgA from infected patients parotid saliva or sera 
are able to recognize the linear peptides 731PEGIEEEGGERDRDTSGRLV750 or 741 
RDRDTSGRLVHGFLAIIWVD762 (Vincent et al., 2004). IEEE epitope is antigenically 
dominant , and competes with the binding of ERDRD-specific antibodies. This situation in 
humans is not known. It is interesting that MAb 1575 appears to have no biological activity 
other than suppression of the antibody response to ERDRD. Furthermore, the sequence 
ERDRD is involved in at least three epitopes. These epitopes may be occulted or exposed as 
a result of conformational changes occurring in another part of gp41, or may be hidden by 
the associated gp120 and exposed when that gp120 is shed. In addition epitopes may be 
modulated by conformational changes that affect the ERDRD sequence directly. (Hollier & 
Dimmock, 2005).  
4. Conclusions 
The development of an HIV vaccine has proven to be a formidable scientific challenge given 
the extreme genetic variability of the virus, lack of good animal models, lack of knowledge 
of all mechanisms involved in immunity or limitations of the technology. However, passive 
administration of rare human anti-Env monoclonal broadly neutralizing antibodies with 
titers that can be achieved by immunization can protect against SHIV challenge in rhesus 
macaques (Hessell et al., 2007; Hessell et al., 2009a; Mascola and Montefiori, 2010; Montefiori 
and Mascola, 2009). Thus, a major goal of HIV-1 vaccine development is to design highly 
immunogenic Env antigens capable of inducing Abs that can broadly neutralize HIV-1 
(Mascola and Montefiori, 2010; Stamatatos et al., 2009).  
According to the clinicaltrials.gov database, more than 543 clinical trials were performed in 
the field of HIV vaccines. During these last ten years, only one vaccine candidate seems to 
give objective protection. This prophylactic vaccine from Sanofi Pasteur is composed by an 
heterologous prime-boost vaccine with a priming with VaxGen gp120 B/E (AIDSVAX B/E) 
protein and a boost with live recombinant ALVAC-HIV (vCP1521). This trial (RV144) has 
involved 16,403 individuals and was conducted in Thailand and completed in October 2009,.  
Vaccination appeared to reduce about 31.2% the rate of acquisition of HIV-1 infection but 
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had no significant effect on viral loads or on CD4+ T cell counts. This “weak” efficacy is the 
first indication that effective vaccination against HIV-1 could be reach and give rease for hopes 
in the developpement of anti-HIV vaccines. The immunological correlates in this trial indicate 
that induction of Nabs is important for vaccine efficacy but not sufficient. Induction of 
polyspecific virus-specific CD8+ T cell responses is also an important actor of vaccine efficacy.  
So the scope of action that remains for an effective vaccination is restricted to early stages of 
infection before the virus infects lymphoid organs and mucosal tissue. In addition, HIV has 
developed during its evolution, an immune system circumvent strategies that really works. 
The data from human clinical trials demonstrate that the first generation of soluble protein 
and vectored Env immunogens was safe and immunogenic. However, generated Abs are 
only effective on highly sensitive strains of HIV-1. One of the major goal in the development 
of an effective vaccine remain to develop a mimetic immunogen similar to viral proteins as 
the most accurate meaning can replicate all possible conformations in steps of infection 
Indeed, conserved Env epitopes targeted by NAbs are poorly immunogenic because they 
either are masked by glycan similar to host carbohydrates (Binley et al., 2010; Wei et al., 
2003), appear transiently (Frey et al., 2008), are sterically hindered (Schief et al., 2009), or 
must overcome entropy for Ab binding. Another important point is that conserved epitopes 
(more in the gp41) present homologies with self-proteins which could trigger tolerance 
mechanisms (Haynes et al., 2005; Verkoczy et al., 2010). Finally, even when Abs can 
neutralize the infecting strains, their effect is transient due to escape mutations (Richman et 
al., 2003; Wei et al., 2003). Thus, immunization of non-human primates and humans with 
HIV-1 Env monomers or trimers has failed to induce broadly NAbs. Induced Abs are mainly 
effective on easily neutralized strains also called Tier 1 strains but have weak neutralization 
abilities for Tier 2 and Tier 3 strains (Gilbert et al., 2010; Mascola and Montefiori, 2010). The 
explanation for the poor cross-reactivity of vaccine-elicited Nabs appears to be related to the 
restricted repertoire of induced Abs and to the complexity of the native viral spike structure. 
NAbs against HIV-1 play an important role in preventing viral infections. Less clear is their 
role in the containment of viral replication in infected individuals.  
However, evidence is accumulating that NAbs may help the cellular arm of the immune 
response to prevent or delay the progression to AIDS. Detection of NAbs depends on the in 
vitro neutralization assays used, and standardization of the assays is essential in order to be 
able to compare the magnitude and quality of a NAb response in sera or other fluids from 
HIV-infected patients, uninfected HIV-1 exposed persons, or vaccinated animals/persons. 
Viral mechanisms to prevent neutralization include high variability and extensive 
glycosylation of the Envelope proteins, Envelope trimerization and shedding as well as late 
exposure of functionally important entry domains by conformational changes induced upon 
CD4 binding. These are also the difficulties encountered in the design of immunogens able 
to induce neutralizing antibodies upon vaccination. 
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